These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34347020)

  • 1. Effects of statins on dopamine loss and prognosis in Parkinson's disease.
    Jeong SH; Lee HS; Chung SJ; Yoo HS; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
    Brain; 2021 Nov; 144(10):3191-3200. PubMed ID: 34347020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
    Jeong SH; Chung SJ; Yoo HS; Hong N; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
    Brain; 2021 May; 144(4):1127-1137. PubMed ID: 33895825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of choroid plexus volume with motor symptoms and dopaminergic degeneration in Parkinson's disease.
    Jeong SH; Park CJ; Jeong HJ; Sunwoo MK; Ahn SS; Lee SK; Lee PH; Kim YJ; Sohn YH; Chung SJ
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1047-1055. PubMed ID: 37399288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
    Jeong SH; Lee HS; Jung JH; Baik K; Lee YH; Yoo HS; Sohn YH; Chung SJ; Lee PH
    Mov Disord; 2021 Jun; 36(6):1411-1419. PubMed ID: 33513293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease.
    Chung SJ; Yoo HS; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
    Parkinsonism Relat Disord; 2018 Jun; 51():43-48. PubMed ID: 29526657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease.
    Lee YH; Cha J; Chung SJ; Yoo HS; Sohn YH; Ye BS; Lee PH
    Sci Rep; 2019 Jul; 9(1):10531. PubMed ID: 31324895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease.
    Jung JH; Na HK; Jeong SH; Chung SJ; Yoo HS; Lee YH; Baik K; Kim SJ; Sohn YH; Lee PH
    Mov Disord; 2023 May; 38(5):843-853. PubMed ID: 36825772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
    Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
    J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical activity mediates the association between striatal dopamine transporter availability and cognition in Parkinson's disease.
    Shih CH; Moore K; Browner N; Sklerov M; Dayan E
    Parkinsonism Relat Disord; 2019 May; 62():68-72. PubMed ID: 30722964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off.
    Chung SJ; Lee Y; Oh JS; Kim JS; Lee PH; Sohn YH
    Parkinsonism Relat Disord; 2018 Aug; 53():96-100. PubMed ID: 29776864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constipation Increases Disability and Decreases Dopamine Levels in the Nigrostriatal System through Gastric Inflammatory Factors in Parkinson's Disease.
    Zhou Y; Su Y; Xu W; Wang W; Yao S
    Curr Neurovasc Res; 2019; 16(3):241-249. PubMed ID: 31258082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.